dimercaprol
BAL (dimercaprol). Approved for sunburns, wind burned, chapped lips. First approved in 1946.
Drug data last refreshed 3h ago · AI intelligence enriched 6mo ago
BAL (dimercaprol) is an injectable chelating agent approved in 1946 for treating heavy metal poisoning, particularly arsenic, mercury, and lead exposure. The product is indicated for sunburns, wind-burned skin, and chapped lips, though these indications appear misaligned with its actual clinical use as a heavy metal antidote. Dimercaprol works by binding to heavy metals and facilitating their urinary excretion.
This aging product approaching loss of exclusivity presents limited commercial growth opportunities and likely operates with a small, maintenance-focused team.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Global Utilization And Registry Database for Improved preservAtion of doNor Pancreata (GUARDIAN-PANCREAS)
Drug-coated Balloons Versus Drug-eluting Stents for the Treatment of Femoropopliteal In-Stent Restenosis
Clinical Evaluation of a Tubal Selective Delivery System
IVUS-Guided Sirolimus-Coated Balloon Versus Sirolimus-Eluting Stent for De Novo Large Vessel Lesions in ACS
Comparison of Fractional FLOW Reserve Outcomes With Drug-Coated Balloon-Based Versus Drug-Eluting Stent-Only Percutaneous Coronary Intervention Strategies
Working on BAL offers limited career upside given its mature lifecycle and zero linked job openings; roles available are typically maintenance-focused in regulatory compliance, medical education, and niche emergency medicine sales. This product is best suited for professionals seeking stable, specialized toxicology expertise rather than high-growth commercial trajectory.